Image credit: The Academy of Sciences
MINSK, 6 May (BelTA) – Chairman of the Presidium of the National Academy of Sciences of Belarus (NASB) Vladimir Karanik discussed promising avenues of advancing bilateral cooperation in the development of new pharmaceutical products with the head of Chokhani Pharma Company Lalit Chokhani in Minsk, the NASB press service told BelTA.
During the meeting special attention was paid to the potential for attracting leading Indian pharmaceutical companies such as Cipla Limited, TEVA, RAKS, and Inventia, the potential for consolidating the joint efforts and sharing the best practices with the Academpharm enterprise.
“Cooperation with these companies, which possess significant experience and manufacturing capacities, is a strategically sound step for us, capable of significantly increasing the competitiveness of the Belarusian pharmaceutical industry,” Vladimir Karanik said.
In his words, Belarus-India interaction in this field opens up new horizons for academic science and for the pharmaceutical industry as a whole.
“The focus is on medications and substances that could satisfy both domestic needs for affordable and high-quality drugs and reach export markets, contributing to the technological sovereignty and strengthening the economic potential of the country,” the head of the National Academy of Sciences stated.
In turn, Lalit Chokhani noted the high scientific potential of Belarusian scientists and the desire of the academic enterprise Academpharm to implement cutting-edge R&D products. He also expressed readiness to provide assistance with promoting joint initiatives and implementing bilateral projects.
The National Academy of Sciences of Belarus is completing the second investment project to expand the production capacity of Academpharm, including as part of a full-cycle process—from research and development to the production of medications. As part of the agreements reached between Chairman of the Presidium of the National Academy of Sciences of Belarus Vladimir Karanik and Chairman of the Board of Directors of Cipla Limited Company Yusuf Hamied, who allocated $1 million in gratuitous aid, a project is being implemented to establish the International Research and Practice Center for Applied Pharmacology.
Follow us on:
